Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative

Ann N Y Acad Sci. 2000:922:324-5. doi: 10.1111/j.1749-6632.2000.tb07055.x.

Authors

J H Lee¹, J M Lee, K H Lim, J K Kim, S K Ahn, Y J Bang, C I Hong

Affiliation

¹ CKD Research Institute, CKD Pharmaceutical Corporation, Seoul 152-600, Korea.

PMID: 11193913
DOI: 10.1111/j.1749-6632.2000.tb07055.x

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacokinetics
Antineoplastic Agents / pharmacology*
Camptothecin / adverse effects*
Camptothecin / analogs & derivatives*
Camptothecin / pharmacokinetics
Camptothecin / pharmacology*
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Humans
Neoplasms / drug therapy*
Neoplasms / metabolism
Topoisomerase I Inhibitors
Tumor Cells, Cultured / drug effects

Substances

Antineoplastic Agents
Topoisomerase I Inhibitors
belotecan
Camptothecin